COVID-19 has opened our eyes to the many communities who don’t have adequate disease detection technology. Ni2o’s RapidTest instrument will allow for a variety of diseases to be detected from samples collected via a non-invasive method, removing the need for specialized testing equipment and personnel.
While we hope to not endure something as devastating as COVID-19 in the near future, another pandemic may be inevitable. A lag in testing can overwhelm labs and hospitals, allowing a contagious disease to spread almost undetected.
Quick Point-of-Care (POC) testing is crucial for ensuring lower pathogen transmissibility. That is why ni2o is beginning development on cartridges to address common diseases such as Influenza A/B, HIV, and Hepatitis.